Results 131 to 140 of about 41,600 (260)

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Genki Sato, Hiroshi Uchino, Takahisa Hirose   +7 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes. [PDF]

Ther Adv Musculoskelet Dis
Chen YH, Byers Kraus V, Chang YS, Lin TM, Lee HY, Chang CK, Kuo TT, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

The miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu, Yu Fang, Meirong Xu, Zuopeng Lu, Yu Cao, Yana Gao   +5 more
wiley   +1 more source

miR-765 induces angiogenesis by inhibiting dipeptidyl peptidase 4 and increasing fibroblast growth factor 2. [PDF]

BBA Adv
Ueno K, Kurazumi H, Murakami J, Mizoguchi T, Suzuki R, Tanaka T, Hamano K.   +6 more
europepmc   +1 more source

Diagnostic performance of SD‐ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy

Journal of Diabetes Investigation, EarlyView.
Study population, methodology and key findings of the study. ABSTRACT Aims This study aimed to evaluate the clinical efficacy of SD‐ΔRR as a novel methodology for short‐duration heart rate variability (HRV) assessment for the diagnosis of diabetic sensorimotor polyneuropathy (DSPN) in patients with diabetes.
Katsuyoshi Katayama, Haruhito A. Uchida, Toshihiko Nagao, Jun Eguchi, Kenji Tsuji, Yoshinori Matsumoto, Ichiro Nojima, Keiko Tanaka, Hidemi Takeuchi, Yasuhiro Onishi, Rika Takemoto, Satoshi Miyamoto, Kenichi Shikata, Jun Wada   +13 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients with COPD and Diabetes: A Nationwide Retrospective Cohort Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Ho CH, Shao YC, Wu YC, Liao KM.
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

Journal of the American College of Cardiology, 2012
openaire   +1 more source

Dipeptidyl Peptidase 4 Inhibitor, an Update [PDF]

The Journal of Korean Diabetes, 2021
openaire   +1 more source

Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Journal of Diabetes Investigation, EarlyView.
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo, Tetsuro Kobayashi, Kyoichiro Tsuchiya   +4 more
wiley   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. [PDF]

Drugs Real World Outcomes
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source